Subscribe to our newsletter to receive the latest product updates and special offers

Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#41 / 200 Total
MPW - Medical Properties Trust Inc - Stock Price Chart
TickerMPW [NYSE]
CompanyMedical Properties Trust Inc
CountryUSA
IndustryREIT - Healthcare Facilities
Market Cap2.65BEPS (ttm)-0.93
P/E-EPS this Y146.39%
Forward P/E8.38EPS next Y22.24%
PEG-EPS past 5Y-
P/S3.04EPS next 5Y-
P/B0.35EPS Q/Q-370.31%
Dividend13.15%Sales Q/Q-132.16%
Insider Own2.02%Inst Own73.31%
Insider Trans0.00%Inst Trans0.48%
Short Float35.20%EarningsFeb 21/b
Analyst Recom3.25Target Price4.95
Avg Volume19.74M52W Range2.92 - 10.74
Medical Properties Trust, Inc. is a self-advised real estate investment trust. It engages in the investment, acquisition, and development of net-leased healthcare facilities. Its property portfolio includes rehabilitation hospitals, long-term acute care hospitals, ambulatory surgery centers, hospitals for women and children, regional and community hospitals, medical office buildings, and other single-discipline facilities. The company was founded by Edward K. Aldag Jr., R. Steven Hamner, Emmett E. McLean, and William Gilliard McKenzie in 2003 and is headquartered in Birmingham, AL.
ENTX - Entera Bio Ltd - Stock Price Chart
TickerENTX [NASD]
CompanyEntera Bio Ltd
CountryIsrael
IndustryBiotechnology
Market Cap70.61MEPS (ttm)-0.31
P/E-EPS this Y19.35%
Forward P/E-EPS next Y-116.00%
PEG-EPS past 5Y25.05%
P/S-EPS next 5Y-
P/B6.80EPS Q/Q36.18%
Dividend-Sales Q/Q-100.00%
Insider Own19.11%Inst Own11.45%
Insider Trans0.97%Inst Trans-4.02%
Short Float0.31%EarningsMar 08/a
Analyst Recom1.00Target Price10.00
Avg Volume220.06K52W Range0.52 - 3.35
Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of orally delivered large molecule therapeutics. It s pipeline include PTH, GLP-E, and hGh, The company was founded on September 30, 2009 and is headquartered in Jerusalem, Israel.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Taitel HayaDirectorJan 12 '24Buy0.999,5009,40535,115Jan 16 08:00 AM
Taitel HayaDirectorJan 10 '24Buy0.777,6155,86425,615Jan 11 06:14 PM
LIEBERMAN GERALD MDirectorDec 22 '23Buy0.7123,95217,006226,961Dec 27 05:00 PM
Toledano Miranda JayneChief Executive OfficerDec 22 '23Buy0.7123,95217,006110,752Dec 27 08:27 AM
Taitel HayaDirectorAug 22 '23Buy0.6218,00011,21618,000Aug 24 08:12 AM
MDJH - MDJM Ltd - Stock Price Chart
TickerMDJH [NASD]
CompanyMDJM Ltd
CountryUnited Kingdom
IndustryReal Estate Services
Market Cap12.15MEPS (ttm)-
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B2.94EPS Q/Q60.60%
Dividend-Sales Q/Q-97.72%
Insider Own87.54%Inst Own0.00%
Insider Trans0.00%Inst Trans-45.98%
Short Float0.00%Earnings-
Analyst Recom-Target Price-
Avg Volume16.47K52W Range0.92 - 3.25
Mdjm Ltd. is a holding company. Through Tianjin Mingda Jiahe Real Estate Co. Ltd., it provides real estate agency services. Its services include real estate consulting services,and independent training. The company was founded on January 26, 2018 and is headquartered in Cupar, the United Kingdom.
MGX - Metagenomi Inc. - Stock Price Chart
TickerMGX [NASD]
CompanyMetagenomi Inc.
CountryUSA
IndustryBiotechnology
Market Cap258.17MEPS (ttm)-
P/E-EPS this Y85.68%
Forward P/E-EPS next Y4.79%
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B-EPS Q/Q-
Dividend-Sales Q/Q-
Insider Own49.18%Inst Own0.00%
Insider Trans5.13%Inst Trans-
Short Float5.23%EarningsMar 28/b
Analyst Recom1.00Target Price21.20
Avg Volume225.06K52W Range7.67 - 12.74
Metagenomi, Inc. is a precision genetic medicines company, which engages in the business of developing next generation gene-editing technologies and therapies. Its business activities include developing gene edit-ing toolbox, ther-a-peu-tic focus, and processing discovery platform. The company was founded by Brian C. Thomas on September 16, 2016 and is headquartered in Emeryville, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Novo Holdings A/S10% OwnerFeb 13 '24Buy15.00800,00012,000,0001,739,175Feb 15 08:38 PM
Novo Holdings A/S10% OwnerFeb 09 '24Buy10.25100,0001,025,000100,000Feb 15 08:38 PM
ADIL - Adial Pharmaceuticals Inc - Stock Price Chart
TickerADIL [NASD]
CompanyAdial Pharmaceuticals Inc
CountryUSA
IndustryBiotechnology
Market Cap7.82MEPS (ttm)-6.43
P/E-EPS this Y47.78%
Forward P/E-EPS next Y15.16%
PEG-EPS past 5Y38.36%
P/S-EPS next 5Y-
P/B0.79EPS Q/Q57.01%
Dividend-Sales Q/Q-
Insider Own6.78%Inst Own6.55%
Insider Trans0.00%Inst Trans-
Short Float0.23%EarningsNov 14/b
Analyst Recom1.67Target Price7.50
Avg Volume6.36M52W Range0.76 - 14.00
Adial Pharmaceuticals, Inc. engages in the development of therapeutics for the treatment or prevention of addiction and related disorders. It offers the AD04, a selective serotonin-3 antagonist. The company was founded by Bankole A. Johnson and William B. Stilley, III in November 2010 and is headquartered in Glen Allen, VA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schuyler KevinDirectorSep 29 '23Buy2.747001,918700Oct 03 08:54 AM
PEPG - PepGen Inc - Stock Price Chart
TickerPEPG [NASD, RUT]
CompanyPepGen Inc
CountryUSA
IndustryBiotechnology
Market Cap341.23MEPS (ttm)-3.30
P/E-EPS this Y12.79%
Forward P/E-EPS next Y4.72%
PEG-EPS past 5Y-172.30%
P/S-EPS next 5Y-
P/B2.31EPS Q/Q-29.94%
Dividend-Sales Q/Q-
Insider Own16.17%Inst Own60.40%
Insider Trans95.79%Inst Trans-0.43%
Short Float1.47%EarningsMar 06/a
Analyst Recom1.00Target Price21.60
Avg Volume136.14K52W Range3.72 - 17.51
PepGen Inc. develops oligonucleotide therapies. It is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. The company was founded in March 26, 2018 and is headquartered in Boston, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RA CAPITAL MANAGEMENT, L.P.DirectorFeb 09 '24Buy10.642,557,59327,212,7909,179,273Feb 13 04:33 PM
McArthur James GPresident and CEONov 30 '23Buy4.171,6947,0561,694Dec 05 07:34 AM
McArthur James GPresident and CEOJun 08 '23Option Exercise2.712,3816,4532,381Jun 09 07:06 PM
McArthur James GPresident and CEOJun 08 '23Sale16.042,38138,1880Jun 09 07:06 PM
McArthur James GPresident and CEOJun 07 '23Option Exercise2.718,41922,8158,419Jun 08 05:23 PM
EBON - Ebang International Holdings Inc - Stock Price Chart
TickerEBON [NASD]
CompanyEbang International Holdings Inc
CountryChina
IndustryComputer Hardware
Market Cap47.94MEPS (ttm)-6.65
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S4.22EPS next 5Y-
P/B0.15EPS Q/Q-
Dividend-Sales Q/Q-
Insider Own23.81%Inst Own6.38%
Insider Trans0.00%Inst Trans-2.94%
Short Float1.17%Earnings-
Analyst Recom-Target Price-
Avg Volume43.73K52W Range5.41 - 18.94
Ebang International Holdings, Inc. is a blockchain technology company, which engages in the research and development of ASIC chip technology used in blockchain applications in China. It also manufactures bitcoin mining machines. The company was founded by Dong Hu in January 2010 and is headquartered in Hangzhou, China.
OCUL - Ocular Therapeutix Inc - Stock Price Chart
TickerOCUL [NASD, RUT]
CompanyOcular Therapeutix Inc
CountryUSA
IndustryBiotechnology
Market Cap775.85MEPS (ttm)-1.26
P/E-EPS this Y17.45%
Forward P/E-EPS next Y-3.15%
PEG-EPS past 5Y8.38%
P/S13.28EPS next 5Y-
P/B6.59EPS Q/Q-71.51%
Dividend-Sales Q/Q5.16%
Insider Own9.13%Inst Own45.02%
Insider Trans21.76%Inst Trans-1.60%
Short Float8.74%EarningsMar 11/a
Analyst Recom1.38Target Price15.50
Avg Volume2.15M52W Range2.00 - 11.31
Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SUMMER ROAD LLC10% OwnerFeb 26 '24Buy7.52930,8517,000,0008,591,401Feb 27 04:43 PM
Mattessich Antony C.President and CEOJan 31 '24Sale4.9518,33890,773427,943Feb 02 07:00 PM
Ozden Rabia GursesChief Medical OfficerJan 31 '24Sale4.957,76438,43292,767Feb 02 07:02 PM
Strassburger Philip C.General CounselJan 31 '24Sale4.956,83133,813109,218Feb 02 07:01 PM
Notman DonaldChief Financial OfficerJan 31 '24Sale4.956,43331,843139,932Feb 02 07:03 PM
ACRV - Acrivon Therapeutics Inc - Stock Price Chart
TickerACRV [NASD, RUT]
CompanyAcrivon Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap289.87MEPS (ttm)-2.73
P/E-EPS this Y-17.34%
Forward P/E-EPS next Y0.48%
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B1.75EPS Q/Q-101.64%
Dividend-Sales Q/Q-
Insider Own44.95%Inst Own62.06%
Insider Trans20.42%Inst Trans-
Short Float3.14%EarningsMar 28/b
Analyst Recom1.00Target Price19.44
Avg Volume723.72K52W Range3.19 - 14.30
Apr-16-24 08:01PM Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316 (GlobeNewswire)
Apr-10-24 08:00AM Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistance Mechanisms to ACR-368 (GlobeNewswire) +8.00%
Apr-09-24 10:32AM ACRV Stock Jumps 55% as Acrivon Therapeutics Gets $130 Million Boost (InvestorPlace) +62.77%
07:00AM Acrivon Therapeutics Announces $130 Million Private Placement Financing (GlobeNewswire)
Mar-30-24 05:31AM Acrivon Therapeutics Inc (ACRV) Reports Increased Annual Loss: A Detailed Look Against Analyst ... (GuruFocus.com)
Mar-28-24 12:52PM ACRV Stock Earnings: Acrivon Therapeutics Misses EPS for Q4 2023 (InvestorPlace) +10.60%
08:00AM Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights (GlobeNewswire)
Mar-05-24 04:30PM Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316 (GlobeNewswire)
Mar-04-24 08:00AM Acrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA, Experienced Board Member and Healthcare Investor, to its Board of Directors (GlobeNewswire) -11.40%
Feb-27-24 08:00AM Acrivon Therapeutics to Participate in a Panel Discussion at the TD Cowen 44th Annual Health Care Conference (GlobeNewswire) +22.07%
Acrivon Therapeutics, Inc. develops drugs for clinical treatment. Its unique precision medicine platform is Acrivon Predictive Precision Proteomics (AP3). AP3 is used to generate proprietary OncoSignature companion diagnostics to identify patients who will benefit from the medicine. The company was founded by Peter Blume-Jensen and Kristina Masson in 2018 and is headquartered in Watertown, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PERCEPTIVE ADVISORS LLC10% OwnerApr 11 '24Buy8.502,353,00020,000,5005,360,858Apr 15 08:53 AM
Chione Ltd10% OwnerJun 26 '23Sale12.93162073,848,632Jun 28 03:47 PM
Holm-Jorgensen RasmusChief Financial OfficerJun 16 '23Option Exercise3.639,50034,48529,530Jun 20 05:21 PM
Chione Ltd10% OwnerJun 15 '23Sale12.142,05624,9603,848,648Jun 20 05:15 PM
Chione Ltd10% OwnerJun 14 '23Sale12.1389310,8323,850,704Jun 14 06:33 PM
GLYC - GlycoMimetics Inc - Stock Price Chart
TickerGLYC [NASD]
CompanyGlycoMimetics Inc
CountryUSA
IndustryBiotechnology
Market Cap124.07MEPS (ttm)-0.58
P/E-EPS this Y-5.17%
Forward P/E-EPS next Y25.82%
PEG-EPS past 5Y13.11%
P/S12406.62EPS next 5Y-
P/B3.23EPS Q/Q27.09%
Dividend-Sales Q/Q-
Insider Own9.46%Inst Own47.09%
Insider Trans0.00%Inst Trans-1.73%
Short Float2.73%EarningsMar 27/b
Analyst Recom1.25Target Price7.00
Avg Volume406.31K52W Range1.11 - 3.53
GlycoMimetics, Inc. engages in the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. It develops proprietary glycomimetics that inhibit disease related functions of carbohydrates. The company was founded by Rachel K. King and John L. Magnani on April 4, 2003 and is headquartered in Rockville, MD.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Rock EdwinChief Medical OfficerSep 22 '23Buy1.3830,40341,956375,403Sep 25 04:21 PM
Rock EdwinChief Medical OfficerSep 21 '23Buy1.3835,00048,300345,000Sep 25 04:21 PM
Koenig ScottDirectorJun 01 '23Option Exercise0.6021,00012,60036,750Jun 02 04:10 PM
Hahn Brian M.SVP Finance, CFOMay 17 '23Sale1.953,7007,21553,143May 18 04:27 PM
JUNIUS DANIEL MDirectorMay 10 '23Buy1.5630,00046,80093,250May 11 05:08 PM
1234567891020